- Prev close
- $206.28
- Day range
- $204.16 – $208.31
- Next earnings
- in 81 days
BIIB’s -0.9% session looks like ordinary stock-specific noise rather than a market-driven move, with the name still supported by a 14.0 forward PE and analyst support that includes a price target raised to $241.
BIIB
BIOGEN INC
As of Aug 5, 2026
60/100
Worth keeping an eye onHealth ScorePrimary driver: stock-specific
BIIB fell -0.9% even though the S&P 500 was -0.2% and the Nasdaq 100 was -0.9%, so the broad tape does not explain the move. Same-sector peers were firmer, with REGN +1.0% and RVMD +2.0% while NTRA was -0.2%, which points to a stock-specific drift rather than a sector-wide selloff. The intraday path also matters: it opened at $210.6, reached $212.18, then finished at $206.63, a fade from early strength rather than a market shock.
Volatility: mostly ordinary
This looks like normal volatility, not a deterioration signal. Revenue is still +0.3% YoY (TTM) and +3.4% YoY in the latest quarter, gross margin is +74.0%, operating margin is +10.9%, and net margin is +8.3%, so the business profile is still profitable and stable. The valuation is mixed: PE 37.0 is not cheap on trailing earnings, while forward PE 14.0 suggests the market is looking through the current EPS -46.0% YoY (TTM) slump. PEG 10.99 is not meaningful here because EPS growth is negative, so it does not provide a clean cheap-or-expensive read. Beta 0.09 also says this name usually moves less than the market, so a -0.9% session is well within normal noise for the stock.
Next earnings: 2026-10-28
The next earnings date is 2026-10-28. The facts here do not include analyst revenue or EPS consensus for that print, so I cannot state expected revenue or EPS growth for the upcoming quarter. What the market will likely focus on, given the current setup, is whether the latest-quarter +3.4% revenue growth can hold, whether the +10.9% operating margin remains intact, and whether the EPS -46.0% YoY (TTM) decline is improving. There is no prior post-earnings reaction data in the facts, so I will not infer a pattern from past prints.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track BIIB with WhyIHold
Get a plain-English explanation the next time BIOGEN INC makes a big move — so you know whether it's benign or worth your attention.